SINGLE-APPLICATION TERBINAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION VERSUS A SINGLE-APPLICATION BUTENAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION FOR THE TREATMENT OF TINEA PEDIS

Phase 2

• Conditions: Tinea Pedis
• Interventions: Drug: TERBINAFINE HYDROCHLORIDE (1%); Drug: BUTENAFINE HYDROCHLORIDE (1%); Drug: Vehicle Control

• Registration Number: NCT03999437
• Lead Sponsor: United Laboratories

Brief Summary

Tinea pedis or athlete's foot is the most common fungal infection worldwide, caused by infection of the feet with dermatophytes such as Trichophyton rubrum, Trichophyton interdigitale (formerly Trichophyton mentagrophytes), and Epidermophyton floccosum. Diagnosis of tinea pedia involves clinical symptoms as well as microscopic examination. Topical therapies are usually applied once or twice daily for as long as 4 weeks, posing a challenge to compliance. The current study aims to test a formulation of the single-dose 1% terbinafine hydrochloride, as well as a single-dose 1% butenafine hydrochloride, versus a vehicle control in adult Filipino patients with athlete's foot. This study will benefit the Filipino community by helping us determine which anti-fungal cream is most effective for athlete's foot.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-01-02
• Status Verified: 2019-06
• Study First Submitted: 2019-06-24
• Study First Submitted QC: 2019-06-24
• Last Update Submitted: 2019-06-24
• Study First Posted: 2019-06-26
• Last Update Posted: 2019-06-26
• Primary Completion: 2019-12-13
• Study Completion: 2020-01-03

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

• Male or nonpregnant females aged 18-60 years old.
• Clinical diagnosis of tinea pedis (total sign/symptom score >2), lesions between the toes, with possible extension to the lateral surfaces and soles of the feet confirmed by a positive microscopy prior to dosing.
• Willing to sign the informed consent.

Exclusion Criteria

• Females who are pregnant (confirmed by a pregnancy test), suspect themselves to be pregnant (even if pregnancy test is negative), breast-feeding, or planning a pregnancy.
• Signs of systemic or other superficial fungal disease (e.g.onychomycosis), clinically relevant abnormal findings upon physical examination of the foot or previous treatment with a disallowed medication (such as corticosteroids).
• Presence of non-healing wounds and/or bacterial infection on the feet.
• Secondary bacterial infection due to tinea pedis
• Presence of pigmentation, extensive scarring, or pigmented lesions in the treatment areas, which could interfere with the rating of efficacy parameters.
• History of hypersensitivity to any component of the test products.
• Current imuunosuppression. Specifically, these include patients with co-morbidities such as diabetes, HIV, chronic diseases requiring maintenance medications, acute febrile/infectious illnesses (i.e. Dengue, pneumonia, etc)
• Use within 3 months prior to baseline of: 1.) chemotherapy, or 2.) radiation therapy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Treatment # 1	TERBINAFINE HYDROCHLORIDE (1%)	-
Treatment # 2	BUTENAFINE HYDROCHLORIDE (1%)	-
Placebo Control	Vehicle Control	-

Primary Outcome Measures

Name	Time	Method
Proportion of participants with effective treatment at week 6	6 weeks	Defined as negative microscopy and improvement in signs and symptoms: mild or no erythema, desquamation or pruritis (\<=1), no vesiculation, and a total sign/symptom score of \<=2.

Trial Locations

Locations (1)

Clinical Trial Management and Testing Associates, Inc.; 🇵🇭 Muntinlupa, Philippines